{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:06:00Z","timestamp":1791396360344,"version":"4.3.3"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,3,19]],"date-time":"2018-03-19T00:00:00Z","timestamp":1521417600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004895","name":"European Social Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s00262-018-2151-y","type":"journal-article","created":{"date-parts":[[2018,3,19]],"date-time":"2018-03-19T09:07:18Z","timestamp":1521450438000},"page":"935-947","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["The novel deubiquitinase inhibitor b-AP15 induces direct and NK cell-mediated antitumor effects in human mantle cell lymphoma"],"prefix":"10.1007","volume":"67","author":[{"given":"Korbinian N.","family":"Kropp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Rothfelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian J.","family":"Schmied","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim L.","family":"Clar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Strunz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Georg","family":"Kopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Steinle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Gr\u00fcnebach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne M.","family":"Rittig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut R.","family":"Salih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0844-2703","authenticated-orcid":false,"given":"Daniela","family":"D\u00f6rfel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,19]]},"reference":[{"issue":"suppl 5","key":"2151_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000439070","volume":"38","author":"KN Kropp","year":"2015","unstructured":"Kropp KN, Strunz B, Kopp HG, Gr\u00fcnebach F, Kanz L, Salih HR, Rittig SM, D\u00f6rfel D (2015) The novel deubiquitinase (DUB) inhibitor b-AP15 induces apoptosis and inhibits proliferation in mantle cell lymphoma. Oncol Res Treatm 38(suppl 5):1\u2013288. \n                    https:\/\/doi.org\/10.1159\/000439070\n                    \n                   [abstract]","journal-title":"Oncol Res Treatm"},{"issue":"10","key":"2151_CR2","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/nrc2230","volume":"7","author":"P Jares","year":"2007","unstructured":"Jares P, Colomer D, Campo E (2007) Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 7(10):750\u2013762. \n                    https:\/\/doi.org\/10.1038\/nrc2230","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2151_CR3","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1182\/blood-2014-05-521898","volume":"125","author":"E Campo","year":"2015","unstructured":"Campo E, Rule S (2015) Mantle cell lymphoma: evolving management strategies. Blood 125(1):48\u201355. \n                    https:\/\/doi.org\/10.1182\/blood-2014-05-521898","journal-title":"Blood"},{"issue":"10044","key":"2151_CR4","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"O Hermine","year":"2016","unstructured":"Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, Szymczyk M, Bouabdallah R, Kneba M, Hallek M, Salles G, Feugier P, Ribrag V, Birkmann J, Forstpointner R, Haioun C, Hanel M, Casasnovas RO, Finke J, Peter N, Bouabdallah K, Sebban C, Fischer T, Duhrsen U, Metzner B, Maschmeyer G, Kanz L, Schmidt C, Delarue R, Brousse N, Klapper W, Macintyre E, Delfau-Larue MH, Pott C, Hiddemann W, Unterhalt M, Dreyling M, European Mantle Cell Lymphoma N (2016) Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet 388(10044):565\u2013575. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(16)00739-X","journal-title":"Lancet"},{"issue":"4","key":"2151_CR5","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","volume":"27","author":"A Herrmann","year":"2009","unstructured":"Herrmann A, Hoster E, Zwingers T, Brittinger G, Engelhard M, Meusers P, Reiser M, Forstpointner R, Metzner B, Peter N, Wormann B, Trumper L, Pfreundschuh M, Einsele H, Hiddemann W, Unterhalt M, Dreyling M (2009) Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 27(4):511\u2013518. \n                    https:\/\/doi.org\/10.1200\/JCO.2008.16.8435","journal-title":"J Clin Oncol"},{"issue":"10","key":"2151_CR6","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1056\/NEJMoa1412096","volume":"372","author":"T Robak","year":"2015","unstructured":"Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O, Pylypenko H, Verhoef G, Siritanaratkul N, Osmanov E, Alexeeva J, Pereira J, Drach J, Mayer J, Hong X, Okamoto R, Pei L, Rooney B, van de Velde H, Cavalli F, Investigators LYM (2015) Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med 372(10):944\u2013953. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1412096","journal-title":"N Engl J Med"},{"issue":"30","key":"2151_CR7","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","volume":"24","author":"RI Fisher","year":"2006","unstructured":"Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, Epner E, Krishnan A, Leonard JP, Lonial S, Stadtmauer EA, O\u2019Connor OA, Shi H, Boral AL, Goy A (2006) Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 24(30):4867\u20134874. \n                    https:\/\/doi.org\/10.1200\/JCO.2006.07.9665","journal-title":"J Clin Oncol"},{"issue":"5","key":"2151_CR8","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1182\/blood-2012-04-403733","volume":"120","author":"P Moreau","year":"2012","unstructured":"Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, Harousseau JL (2012) Proteasome inhibitors in multiple myeloma: 10 years later. Blood 120(5):947\u2013959. \n                    https:\/\/doi.org\/10.1182\/blood-2012-04-403733","journal-title":"Blood"},{"issue":"2","key":"2151_CR9","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1182\/blood-2010-02-269514","volume":"117","author":"P Perez-Galan","year":"2011","unstructured":"Perez-Galan P, Mora-Jensen H, Weniger MA, Shaffer AL 3rd, Rizzatti EG, Chapman CM, Mo CC, Stennett LS, Rader C, Liu P, Raghavachari N, Stetler-Stevenson M, Yuan C, Pittaluga S, Maric I, Dunleavy KM, Wilson WH, Staudt LM, Wiestner A (2011) Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation. Blood 117(2):542\u2013552. \n                    https:\/\/doi.org\/10.1182\/blood-2010-02-269514","journal-title":"Blood"},{"issue":"11","key":"2151_CR10","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1158\/1535-7163.MCT-13-0156","volume":"12","author":"L Zhang","year":"2013","unstructured":"Zhang L, Pham LV, Newberry KJ, Ou Z, Liang R, Qian J, Sun L, Blonska M, You Y, Yang J, Lin X, Rollo A, Tamayo AT, Lee J, Ford RJ, Zhao X, Kwak LW, Yi Q, Wang M (2013) In vitro and in vivo therapeutic efficacy of carfilzomib in mantle cell lymphoma: targeting the immunoproteasome. Mol Cancer Ther 12(11):2494\u20132504. \n                    https:\/\/doi.org\/10.1158\/1535-7163.MCT-13-0156","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"2151_CR11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s12079-011-0121-7","volume":"5","author":"LJ Crawford","year":"2011","unstructured":"Crawford LJ, Walker B, Irvine AE (2011) Proteasome inhibitors in cancer therapy. J Cell Commun Signal 5(2):101\u2013110. \n                    https:\/\/doi.org\/10.1007\/s12079-011-0121-7","journal-title":"J Cell Commun Signal"},{"issue":"12","key":"2151_CR12","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/nm.2536","volume":"17","author":"P D\u2019Arcy","year":"2011","unstructured":"D\u2019Arcy P, Brnjic S, Olofsson MH, Fryknas M, Lindsten K, De Cesare M, Perego P, Sadeghi B, Hassan M, Larsson R, Linder S (2011) Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat Med 17(12):1636\u20131640. \n                    https:\/\/doi.org\/10.1038\/nm.2536","journal-title":"Nat Med"},{"issue":"6","key":"2151_CR13","doi-asserted-by":"publisher","first-page":"4159","DOI":"10.18632\/oncotarget.2904","volume":"6","author":"RI Vogel","year":"2015","unstructured":"Vogel RI, Coughlin K, Scotti A, Iizuka Y, Anchoori R, Roden RB, Marastoni M, Bazzaro M (2015) Simultaneous inhibition of deubiquitinating enzymes (DUBs) and autophagy synergistically kills breast cancer cells. Oncotarget 6(6):4159\u20134170. \n                    https:\/\/doi.org\/10.18632\/oncotarget.2904","journal-title":"Oncotarget"},{"key":"2151_CR14","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.biocel.2016.08.038","volume":"79","author":"X Chen","year":"2016","unstructured":"Chen X, Wu J, Chen Y, Ye D, Lei H, Xu H, Yang L, Wu Y, Gu W (2016) Ubiquitin-specific protease 14 regulates cell proliferation and apoptosis in oral squamous cell carcinoma. Int J Biochem Cell Biol 79:350\u2013359. \n                    https:\/\/doi.org\/10.1016\/j.biocel.2016.08.038","journal-title":"Int J Biochem Cell Biol"},{"issue":"3","key":"2151_CR15","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.exphem.2013.11.010","volume":"42","author":"X Feng","year":"2014","unstructured":"Feng X, Holmlund T, Zheng C, Fadeel B (2014) Proapoptotic effects of the novel proteasome inhibitor b-AP15 on multiple myeloma cells and natural killer cells. Exp Hematol 42(3):172\u2013182. \n                    https:\/\/doi.org\/10.1016\/j.exphem.2013.11.010","journal-title":"Exp Hematol"},{"issue":"5","key":"2151_CR16","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1182\/blood-2013-05-500033","volume":"123","author":"Z Tian","year":"2014","unstructured":"Tian Z, D\u2019Arcy P, Wang X, Ray A, Tai YT, Hu Y, Carrasco RD, Richardson P, Linder S, Chauhan D, Anderson KC (2014) A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood 123(5):706\u2013716. \n                    https:\/\/doi.org\/10.1182\/blood-2013-05-500033","journal-title":"Blood"},{"issue":"3","key":"2151_CR17","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/bjh.13304","volume":"169","author":"K Chitta","year":"2015","unstructured":"Chitta K, Paulus A, Akhtar S, Blake MK, Caulfield TR, Novak AJ, Ansell SM, Advani P, Ailawadhi S, Sher T, Linder S, Chanan-Khan A (2015) Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenstrom macroglobulinaemia tumour cells. Br J Haematol 169(3):377\u2013390. \n                    https:\/\/doi.org\/10.1111\/bjh.13304","journal-title":"Br J Haematol"},{"issue":"5","key":"2151_CR18","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1111\/cbdd.12571","volume":"86","author":"X Wang","year":"2015","unstructured":"Wang X, D\u2019Arcy P, Caulfield TR, Paulus A, Chitta K, Mohanty C, Gullbo J, Chanan-Khan A, Linder S (2015) Synthesis and evaluation of derivatives of the proteasome deubiquitinase inhibitor b-AP15. Chem Biol Drug Des 86(5):1036\u20131048. \n                    https:\/\/doi.org\/10.1111\/cbdd.12571","journal-title":"Chem Biol Drug Des"},{"issue":"11","key":"2151_CR19","doi-asserted-by":"publisher","first-page":"e492","DOI":"10.1038\/bcj.2016.93","volume":"6","author":"A Paulus","year":"2016","unstructured":"Paulus A, Akhtar S, Caulfield TR, Samuel K, Yousaf H, Bashir Y, Paulus SM, Tran D, Hudec R, Cogen D, Jiang J, Edenfield B, Novak A, Ansell SM, Witzig T, Martin P, Coleman M, Roy V, Ailawadhi S, Chitta K, Linder S, Chanan-Khan A (2016) Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells. Blood Cancer J 6(11):e492. \n                    https:\/\/doi.org\/10.1038\/bcj.2016.93","journal-title":"Blood Cancer J"},{"issue":"15","key":"2151_CR20","doi-asserted-by":"publisher","first-page":"4525","DOI":"10.1158\/0008-5472.CAN-16-1040","volume":"76","author":"N Shukla","year":"2016","unstructured":"Shukla N, Somwar R, Smith RS, Ambati S, Munoz S, Merchant M, D\u2019Arcy P, Wang X, Kobos R, Antczak C, Bhinder B, Shum D, Radu C, Yang G, Taylor BS, Ng CK, Weigelt B, Khodos I, de Stanchina E, Reis-Filho JS, Ouerfelli O, Linder S, Djaballah H, Ladanyi M (2016) Proteasome addiction defined in ewing sarcoma is effectively targeted by a novel class of 19S proteasome inhibitors. Cancer Res 76(15):4525\u20134534. \n                    https:\/\/doi.org\/10.1158\/0008-5472.can-16-1040","journal-title":"Cancer Res"},{"issue":"21","key":"2151_CR21","doi-asserted-by":"publisher","first-page":"30962","DOI":"10.18632\/oncotarget.8821","volume":"7","author":"RI Vogel","year":"2016","unstructured":"Vogel RI, Pulver T, Heilmann W, Mooneyham A, Mullany S, Zhao X, Shahi M, Richter J, Klein M, Chen L, Ding R, Konecny G, Kommoss S, Winterhoff B, Ghebre R, Bazzaro M (2016) USP14 is a predictor of recurrence in endometrial cancer and a molecular target for endometrial cancer treatment. Oncotarget 7(21):30962\u201330976. \n                    https:\/\/doi.org\/10.18632\/oncotarget.8821","journal-title":"Oncotarget"},{"key":"2151_CR22","doi-asserted-by":"publisher","first-page":"26979","DOI":"10.1038\/srep26979","volume":"6","author":"X Wang","year":"2016","unstructured":"Wang X, Mazurkiewicz M, Hillert EK, Olofsson MH, Pierrou S, Hillertz P, Gullbo J, Selvaraju K, Paulus A, Akhtar S, Bossler F, Khan AC, Linder S, D\u2019Arcy P (2016) The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells. Sci Rep 6:26979. \n                    https:\/\/doi.org\/10.1038\/srep26979","journal-title":"Sci Rep"},{"issue":"13","key":"2151_CR23","doi-asserted-by":"publisher","first-page":"21115","DOI":"10.18632\/oncotarget.15501","volume":"8","author":"M Mazurkiewicz","year":"2017","unstructured":"Mazurkiewicz M, Hillert EK, Wang X, Pellegrini P, Olofsson MH, Selvaraju K, D\u2019Arcy P, Linder S (2017) Acute lymphoblastic leukemia cells are sensitive to disturbances in protein homeostasis induced by proteasome deubiquitinase inhibition. Oncotarget 8(13):21115\u201321127. \n                    https:\/\/doi.org\/10.18632\/oncotarget.15501","journal-title":"Oncotarget"},{"issue":"8","key":"2151_CR24","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s00262-013-1439-1","volume":"62","author":"D Sarhan","year":"2013","unstructured":"Sarhan D, Wennerberg E, D\u2019Arcy P, Gurajada D, Linder S, Lundqvist A (2013) A novel inhibitor of proteasome deubiquitinating activity renders tumor cells sensitive to TRAIL-mediated apoptosis by natural killer cells and T cells. Cancer Immunol Immunother 62(8):1359\u20131368. \n                    https:\/\/doi.org\/10.1007\/s00262-013-1439-1","journal-title":"Cancer Immunol Immunother"},{"key":"2151_CR25","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1146\/annurev-immunol-031210-101324","volume":"29","author":"MD Vesely","year":"2011","unstructured":"Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ (2011) Natural innate and adaptive immunity to cancer. Annu Rev Immunol 29:235\u2013271. \n                    https:\/\/doi.org\/10.1146\/annurev-immunol-031210-101324","journal-title":"Annu Rev Immunol"},{"issue":"12","key":"2151_CR26","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1084\/jem.188.12.2375","volume":"188","author":"L Zamai","year":"1998","unstructured":"Zamai L, Ahmad M, Bennett IM, Azzoni L, Alnemri ES, Perussia B (1998) Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med 188(12):2375\u20132380","journal-title":"J Exp Med"},{"issue":"3","key":"2151_CR27","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1084\/jem.181.3.1235","volume":"181","author":"H Arase","year":"1995","unstructured":"Arase H, Arase N, Saito T (1995) Fas-mediated cytotoxicity by freshly isolated natural killer cells. J Exp Med 181(3):1235\u20131238","journal-title":"J Exp Med"},{"issue":"11","key":"2151_CR28","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.1002\/(SICI)1521-4141(199911)29:11<3588::AID-IMMU3588>3.0.CO;2-O","volume":"29","author":"G Caron","year":"1999","unstructured":"Caron G, Delneste Y, Aubry JP, Magistrelli G, Herbault N, Blaecke A, Meager A, Bonnefoy JY, Jeannin P (1999) Human NK cells constitutively express membrane TNF-alpha (mTNFalpha) and present mTNFalpha-dependent cytotoxic activity. Eur J Immunol 29(11):3588\u20133595","journal-title":"Eur J Immunol"},{"issue":"1","key":"2151_CR29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1365-2567.2009.03123.x","volume":"128","author":"NJ Topham","year":"2009","unstructured":"Topham NJ, Hewitt EW (2009) Natural killer cell cytotoxicity: how do they pull the trigger? Immunology 128(1):7\u201315. \n                    https:\/\/doi.org\/10.1111\/j.1365-2567.2009.03123.x","journal-title":"Immunology"},{"key":"2151_CR30","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1146\/annurev.immunol.23.021704.115526","volume":"23","author":"LL Lanier","year":"2005","unstructured":"Lanier LL (2005) NK cell recognition. Annu Rev Immunol 23:225\u2013274. \n                    https:\/\/doi.org\/10.1146\/annurev.immunol.23.021704.115526","journal-title":"Annu Rev Immunol"},{"key":"2151_CR31","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1146\/annurev-immunol-032712-095951","volume":"31","author":"DH Raulet","year":"2013","unstructured":"Raulet DH, Gasser S, Gowen BG, Deng W, Jung H (2013) Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol 31:413\u2013441. \n                    https:\/\/doi.org\/10.1146\/annurev-immunol-032712-095951","journal-title":"Annu Rev Immunol"},{"issue":"10","key":"2151_CR32","doi-asserted-by":"publisher","first-page":"e26097","DOI":"10.4161\/onci.26097","volume":"2","author":"E Ullrich","year":"2013","unstructured":"Ullrich E, Koch J, Cerwenka A, Steinle A (2013) New prospects on the NKG2D\/NKG2DL system for oncology. Oncoimmunology 2(10):e26097. \n                    https:\/\/doi.org\/10.4161\/onci.26097","journal-title":"Oncoimmunology"},{"issue":"11","key":"2151_CR33","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-07-4744","volume":"14","author":"S Armeanu","year":"2008","unstructured":"Armeanu S, Krusch M, Baltz KM, Weiss TS, Smirnow I, Steinle A, Lauer UM, Bitzer M, Salih HR (2008) Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma. Clin Cancer Res 14(11):3520\u20133528. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-4744","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2151_CR34","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1158\/0008-5472.CAN-07-2973","volume":"68","author":"M Vales-Gomez","year":"2008","unstructured":"Vales-Gomez M, Chisholm SE, Cassady-Cain RL, Roda-Navarro P, Reyburn HT (2008) Selective induction of expression of a ligand for the NKG2D receptor by proteasome inhibitors. Cancer Res 68(5):1546\u20131554. \n                    https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-2973","journal-title":"Cancer Res"},{"issue":"15","key":"2151_CR35","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1182\/blood-2008-08-173914","volume":"113","author":"A Soriani","year":"2009","unstructured":"Soriani A, Zingoni A, Cerboni C, Iannitto ML, Ricciardi MR, Di Gialleonardo V, Cippitelli M, Fionda C, Petrucci MT, Guarini A, Foa R, Santoni A (2009) ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood 113(15):3503\u20133511. \n                    https:\/\/doi.org\/10.1182\/blood-2008-08-173914","journal-title":"Blood"},{"issue":"3","key":"2151_CR36","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.4049\/jimmunol.1200796","volume":"189","author":"J Hilpert","year":"2012","unstructured":"Hilpert J, Grosse-Hovest L, Grunebach F, Buechele C, Nuebling T, Raum T, Steinle A, Salih HR (2012) Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses. J Immunol 189(3):1360\u20131371. \n                    https:\/\/doi.org\/10.4049\/jimmunol.1200796","journal-title":"J Immunol"},{"issue":"12","key":"2151_CR37","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1002\/ijc.25635","volume":"128","author":"BJ Schmiedel","year":"2011","unstructured":"Schmiedel BJ, Arelin V, Gruenebach F, Krusch M, Schmidt SM, Salih HR (2011) Azacytidine impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulation. Int J Cancer 128(12):2911\u20132922. \n                    https:\/\/doi.org\/10.1002\/ijc.25635","journal-title":"Int J Cancer"},{"issue":"6","key":"2151_CR38","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.3892\/or.2015.4296","volume":"34","author":"G Huang","year":"2015","unstructured":"Huang G, Li L, Zhou W (2015) USP14 activation promotes tumor progression in hepatocellular carcinoma. Oncol Rep 34(6):2917\u20132924. \n                    https:\/\/doi.org\/10.3892\/or.2015.4296","journal-title":"Oncol Rep"},{"issue":"4","key":"2151_CR39","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1182\/blood-2003-01-0019","volume":"102","author":"HR Salih","year":"2003","unstructured":"Salih HR, Antropius H, Gieseke F, Lutz SZ, Kanz L, Rammensee HG, Steinle A (2003) Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 102(4):1389\u20131396. \n                    https:\/\/doi.org\/10.1182\/blood-2003-01-0019","journal-title":"Blood"},{"issue":"10","key":"2151_CR40","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1096\/fj.06-7724com","volume":"21","author":"KM Baltz","year":"2007","unstructured":"Baltz KM, Krusch M, Bringmann A, Brossart P, Mayer F, Kloss M, Baessler T, Kumbier I, Peterfi A, Kupka S, Kroeber S, Menzel D, Radsak MP, Rammensee HG, Salih HR (2007) Cancer immunoediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell\/tumor cell interactions. FASEB J 21(10):2442\u20132454. \n                    https:\/\/doi.org\/10.1096\/fj.06-7724com","journal-title":"FASEB J"},{"issue":"10","key":"2151_CR41","doi-asserted-by":"publisher","first-page":"6600","DOI":"10.4049\/jimmunol.0801214","volume":"182","author":"JE Butler","year":"2009","unstructured":"Butler JE, Moore MB, Presnell SR, Chan HW, Chalupny NJ, Lutz CT (2009) Proteasome regulation of ULBP1 transcription. J Immunol 182(10):6600\u20136609. \n                    https:\/\/doi.org\/10.4049\/jimmunol.0801214","journal-title":"J Immunol"},{"issue":"38","key":"2151_CR42","doi-asserted-by":"publisher","first-page":"63232","DOI":"10.18632\/oncotarget.18774","volume":"8","author":"J Cai","year":"2017","unstructured":"Cai J, Xia X, Liao Y, Liu N, Guo Z, Chen J, Yang L, Long H, Yang Q, Zhang X, Xiao L, Wang X, Huang H, Liu J (2017) A novel deubiquitinase inhibitor b-AP15 triggers apoptosis in both androgen receptor-dependent and -independent prostate cancers. Oncotarget 8(38):63232\u201363246. \n                    https:\/\/doi.org\/10.18632\/oncotarget.18774","journal-title":"Oncotarget"},{"issue":"14","key":"2151_CR43","doi-asserted-by":"publisher","first-page":"7317","DOI":"10.1158\/0008-5472.CAN-06-0680","volume":"66","author":"A Lundqvist","year":"2006","unstructured":"Lundqvist A, Abrams SI, Schrump DS, Alvarez G, Suffredini D, Berg M, Childs R (2006) Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res 66(14):7317\u20137325. \n                    https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-0680","journal-title":"Cancer Res"},{"issue":"1","key":"2151_CR44","doi-asserted-by":"publisher","first-page":"163","DOI":"10.4049\/jimmunol.180.1.163","volume":"180","author":"WH Hallett","year":"2008","unstructured":"Hallett WH, Ames E, Motarjemi M, Barao I, Shanker A, Tamang DL, Sayers TJ, Hudig D, Murphy WJ (2008) Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition. J Immunol 180(1):163\u2013170","journal-title":"J Immunol"},{"issue":"29","key":"2151_CR45","doi-asserted-by":"publisher","first-page":"26982","DOI":"10.18632\/oncotarget.4831","volume":"6","author":"G Yang","year":"2015","unstructured":"Yang G, Gao M, Zhang Y, Kong Y, Gao L, Tao Y, Han Y, Wu H, Meng X, Xu H, Zhan F, Wu X, Shi J (2015) Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I. Oncotarget 6(29):26982\u201326994. \n                    https:\/\/doi.org\/10.18632\/oncotarget.4831","journal-title":"Oncotarget"},{"issue":"1","key":"2151_CR46","doi-asserted-by":"publisher","first-page":"8027","DOI":"10.1038\/s41598-017-08424-w","volume":"7","author":"YT Oh","year":"2017","unstructured":"Oh YT, Deng L, Deng J, Sun SY (2017) The proteasome deubiquitinase inhibitor b-AP15 enhances DR5 activation-induced apoptosis through stabilizing DR5. Sci Rep 7(1):8027. \n                    https:\/\/doi.org\/10.1038\/s41598-017-08424-w","journal-title":"Sci Rep"},{"issue":"4","key":"2151_CR47","doi-asserted-by":"publisher","first-page":"470","DOI":"10.3324\/haematol.13783","volume":"94","author":"X Wang","year":"2009","unstructured":"Wang X, Ottosson A, Ji C, Feng X, Nordenskjold M, Henter JI, Fadeel B, Zheng C (2009) Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxicity. Haematologica 94(4):470\u2013478. \n                    https:\/\/doi.org\/10.3324\/haematol.13783","journal-title":"Haematologica"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-018-2151-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2151-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2151-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,18]],"date-time":"2019-03-18T20:07:36Z","timestamp":1552939656000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-018-2151-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,19]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["2151"],"URL":"https:\/\/doi.org\/10.1007\/s00262-018-2151-y","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,19]]},"assertion":[{"value":"23 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by our institutional review board, the ethics committee of the Faculty of Medicine of the Eberhard Karls Universit\u00e4t T\u00fcbingen and of the University Hospital T\u00fcbingen (reference number 13\/2007V) to be in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"Buffy coat preparations were produced by the local blood bank after obtaining informed consent, in accordance with the principles of the Declaration of Helsinki and its later amendments. Peripheral blood samples from MCL patients were obtained after written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"MCL cells were purchased from DSMZ and ATCC for this project.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Cell line authentication"}}]}}